Table 3.
Serological characteristics of the study group with and without arterial hypertension
| Variable | SSc AH (+) – 45 | SSc AH (–) – 63 | P < 0.05 |
|---|---|---|---|
| aCL | 6 (13.3%) | 4 (6.3%) | NS |
| LAC | 2 (4.4%) | 1 (1.6%) | NS |
| Anti-topo I (Scl-70) | 16 (35.6%) | 29 (46%) | NS |
| Anti-centromere | 6 (13.3%) | 15 (23.8%) | NS |
| Anti-RNA Pol III | 9 (15.8%) | 7 (10%) | NS |
| Anti-Th/To | 0 (0%) | 2 (3.2 %) | NS |
| Anti-Ku | 2 (4.4%) | 1 (1.6%) | NS |
| Anti-PmScl | 7 (15.5%) | 9 (14.3%) | NS |
| Anti-NOR-90 | 3 (6.7%) | 3 (4.8%) | NS |
| Anti-PDGFR | 0 (0%) | 0 (0%) | NS |
| Anti-SSA/Ro52 | 10 (22.2%) | 19 (30%) | NS |
aCL– anticardiolipin antibodies, LAC – lupus anticoagulant. Data were presented as numbers and percentages. P-value of < 0.05 was considered statistically significant.